Focus: Mineralys is a public-stage small-molecule biotech focused on cardiovascular and nephrology indications, headquartered in Radnor, PA. The company is advancing lorundrostat across hypertension, chronic kidney disease, and obstructive sleep apnea.
Profile data last refreshed 40m ago · AI intelligence enriched 2mo ago
Hot — 36 jobs added in 30d
Net +25 (36 new, 11 removed). Aggressive expansion phase.
Mineralys is a clinical-stage biotech with near-term catalysts and public-market liquidity, but faces material cash runway and execution risk—suitable for risk-tolerant candidates seeking high-impact roles in a growing organization.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Mineralys Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Mineralys Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
[144] Mineralys Therapeutics, Inc. SEC Filing - Stock Titan
[144] Mineralys Therapeutics, Inc. SEC Filing Stock Titan
Precision Trading with Mineralys Therapeutics Inc. (MLYS) Risk Zones - Stock Traders Daily
Precision Trading with Mineralys Therapeutics Inc. (MLYS) Risk Zones Stock Traders Daily
Mineralys (MLYS) raises ~$150M in $26.50/share offering to fund royalty repurchase - Stock Titan
Mineralys (MLYS) raises ~$150M in $26.50/share offering to fund royalty repurchase Stock Titan
Mineralys Therapeutics, Inc. Enters into Senior Secured Term Loan Agreement for Up to $500 Million - marketscreener.com
Mineralys Therapeutics, Inc. Enters into Senior Secured Term Loan Agreement for Up to $500 Million marketscreener.com
Mineralys (NASDAQ: MLYS) gets $500M loan, ends lorundrostat royalty payments - Stock Titan
Mineralys (NASDAQ: MLYS) gets $500M loan, ends lorundrostat royalty payments Stock Titan
Mineralys (Nasdaq: MLYS) prices $150M stock sale to fund $200M royalty buyback - Stock Titan
Mineralys (Nasdaq: MLYS) prices $150M stock sale to fund $200M royalty buyback Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 7 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo